( May 14, 2026, 11:51 AM EDT) -- HOUSTON — Eli Lilly & Co. failed to demonstrate how actions by a compounding pharmacy that sells a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes and weight loss, caused it to lose sales or suffer “irreparable harm to its brand or consumer goodwill,” a Texas federal judge said in granting a motion to dismiss Lanham Act claims against Empower Clinic Services LLC....